Chemical Exchange Saturation Transfer MR Imaging is Superior to Diffusion-Tensor Imaging in the Diagnosis and Severity Evaluation of Parkinson's Disease: A Study on Substantia Nigra and Striatum.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by nigrostriatal cell loss. To date, the diagnosis of PD is still based primarily on the clinical manifestations, which may be typical and obvious only in advanced-stage PD. Thus, it is crucial to find a reliable marker for the diagnosis of PD. We conducted this study to assess the diagnostic efficiency of chemical exchange saturation transfer (CEST) imaging and diffusion-tensor imaging (DTI) in PD at 3 T by evaluating changes on substantia nigra and striatum. Twenty-three PD patients and twenty-three age-matched normal controls were recruited. All patients and controls were imaged on a 3-T MR system, using an eight-channel head coil. CEST imaging was acquired in two transverse slices of the head, including substantia nigra and striatum. The magnetization transfer ratio asymmetry at 3.5 ppm, MTRasym(3.5 ppm), and the total CEST signal intensity between 0 and 4 ppm were calculated. Multi-slice DTI was acquired for all the patients and normal controls. Quantitative analysis was performed on the substantia nigra, globus pallidus, putamen, and caudate. The MTRasym(3.5 ppm) value, the total CEST signal intensity, and fractional anisotropy value of the substantia nigra were all significantly lower in PD patients than in normal controls (P = 0.003, P = 0.004, and P < 0.001, respectively). The MTRasym(3.5 ppm) values of the putamen and the caudate were significantly higher in PD patients than in normal controls (P = 0.010 and P = 0.009, respectively). There were no significant differences for the mean diffusivity in these four regions between PD patients and normal controls. In conclusion, CEST MR imaging provided multiple CEST image contrasts in the substantia nigra and the striatum in PD and may be superior to DTI in the diagnosis of PD.

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by nigrostriatal cell loss, resulting in striatal dopamine deficiency (Dauer and Przedborski, 2003). Accurate diagnosis in early stage of PD and early initiation of therapy may provide benefit for the patient (Olanow et al., 2009). Unfortunately, to date, the diagnosis of PD is still based primarily on the clinical manifestations, which may be typical and obvious only in advanced-stage PD. Thus, it is crucial to find a reliable marker for the diagnosis of PD.

Several functional MR imaging have been used to assist in the PD diagnosis, including diffusion-tensor imaging (DTI). Based on the diffusivity of water molecules, which exhibit a varying degree of tissue dependent anisotropy, two primary DTI parameters, fractional anisotropy (FA) and mean diffusivity (MD) or apparent diffusion coefficient (ADC), are associated with the directionality (anisotropy) and magnitude (diffusivity) of water diffusion, respectively (Hagmann et al., 2006). DTI has typically been used to detect axon and myelin injury in white matter of PD patients (Cnyrim et al., 2014; Kamagata et al., 2014), while some studies have also focused on evaluating the abnormalities in gray matter (Prakash et al., 2012; Zhan et al., 2012; Lenfeldt et al., 2013).

Recently, a relatively new MR technique, chemical exchange saturation transfer (CEST) imaging (Zhou and van Zijl, 2006; Kogan et al., 2013; Vinogradov et al., 2013), or more specifically, amide proton transfer (APT) MR imaging (Zhou et al., 2003), has been used to assess PD (Li et al., 2014). CEST imaging is a specific type of magnetization transfer imaging [that is sensitive to solid-like proteins in tissue (van Buchem and Tofts, 2000; Henkelman et al., 2001)]. It has recently emerged as an important contrast mechanism for MRI in the field of molecular and cellular imaging. The recent study of CEST in PD focused on the gray matter of midbrain and basal ganglia. The result indicated the potential of the CEST signal as a marker of PD (Li et al., 2014).

The aim of this study was to compare the diagnostic efficiency of the DTI and CEST techniques in PD, by evaluating the changes of substantia nigra and striatum (globus pallidus, putamen, and caudate).

Materials and Methods

Patients and Controls

A total of 23 PD patients (13 men and 10 women; mean age, 65.5 years; range, 46–77 years; 12.2 ± 4.3 years of education) and 23 age- and education-matched normal controls (13 men and 10 women; mean age, 64.3 years; range, 50–72 years; 12.8 ± 3.6 years of education) were recruited in this study. All patients were right-handed. Informed consent was acquired from each subject prior to participation in this study. The study was approved by the local Institutional Review Board.

Parkinson’s disease diagnosis was confirmed by an experienced movement disorder specialist according to published criteria (Hughes et al., 1992, 2001). The patients fulfilled the UK Brain Bank criteria for idiopathic PD. All PD patients were assessed with the Hoehn and Yahr (H&Y) scale by the same movement disorder specialist after overnight withdrawal of antiparkinson medication for at least 12 h.

The exclusion criteria for subjects in this study were as follows: head trauma; central nervous system infection; a history of stroke; exposure to anti-dopaminergic drugs; or other neurologic or psychiatric diseases and any structural abnormalities on brain magnetic resonance images.

MRI Acquisition

All subjects were imaged on a 3T Philips MRI system (Achieva 3.0T; Philips Medical Systems, Best, The Netherlands), with a dual-channel body coil for transmission and an eight-channel sensitivity-encoding coil for reception. Pencil beam second-order shimming was employed. The PD patients were scanned shortly after the neurological assessment. Routine images, including axial T2-weighted, T1-weighted, and fluid-attenuated inversion recovery (FLAIR), were acquired first to exclude structural abnormality.

CEST/APT Imaging

The CEST/APT imaging sequence was based on a pseudo-continuous wave, off-resonance RF irradiation (saturation duration = 200 ms × 4; inter-pulse delay, 10 ms; power level = 2 μT) and a single-shot, turbo-spin-echo readout. The parameters were as follows: repetition time = 3000 ms; echo time = 7.9 ms; turbo-spin-echo factor = 54; field of view = 230 mm × 221 mm; matrix = 105 × 100; and slice thickness = 6 mm. Two transverse slices of the head were acquired, including the basal ganglia and midbrain. A multi-offset, multi-acquisition CEST/APT imaging protocol, as reported before (Li et al., 2014), was used. The 31 offsets were 0, ±0.25, ±0.5, ±0.75, ±1 (2), ±1.5 (2), ±2 (2), ±2.5 (2), ±3 (2), ±3.25 (2), ±3.5 (8), ±3.75 (2), ±4 (2), ±4.5, ±5, and ±6 ppm (the values in parentheses represented the number of acquisitions, which was 1, if not specified). An unsaturated image was acquired for the signal normalization. The acquisition time was about 3 min per slice.

Diffusion-Tensor Imaging

The parameters were as follows: repetition time = shortest (actual TR = 5472 ms); echo time = shortest (actual TE: 93 ms); b values = 0, 1000 s/mm2; diffusion gradient directions = 31; field of view = 240 mm × 240 mm; matrix = 128 × 128; number of excitations = 1; slice thickness = 3 mm; gap = 0; and slice number = 40. The acquisition time was about 7.5 min.

Imaging Processing

The APT imaging analysis was performed using in-house developed software, based on the Interactive Data Language (IDL, ITT Visual Information Solutions, Boulder, CO, USA) environment. The measured magnetization transfer spectra (Ssat/S0, in which Ssat and S0 are the signal intensities with and without selective RF irradiation, respectively, plotted as a function of saturation frequency offset, relative to water) were corrected for field inhomogeneity effects on a pixel-by-pixel basis. CEST imaging is usually quantified through the magnetization transfer ratio (MTR = 1 − Ssat/S0) asymmetry (MTRasym) analysis with respect to the water resonance:

We defined the total CEST signal intensity, , as the integral of the MTRasym spectrum in the range of 0–4 ppm.

Specifically for APT imaging, we have: where APTR is the proton transfer ratio for the amide protons associated with mobile cellular proteins and peptides in tissue. was previously thought to be the inherent MTRasym of the solid-phase magnetization transfer effect (Zhou et al., 2008). However, the semi-solid conventional magnetization transfer effect was thought to be symmetrical around the water resonance due to a very broad-spectrum distribution. Several recent studies suggest that could be dominated by the possible intramolecular or intermolecular nuclear Overhauser enhancement effect of the upfield non-exchangeable protons (such as aliphatic protons) of mobile to relatively less mobile cellular macromolecules and metabolites (Zhou et al., 2013a; Heo et al., 2015). To account for these confounding factors, the MTRasym(3.5 ppm) images calculated by Eq. 2 are, in principle, APT-weighted images.

The quantitative image analysis was performed by two radiologists (CL and RW, who had 5 and 10 years of experience in brain imaging, respectively). The FLAIR images were used as the anatomical reference to draw regions of interest (ROIs; substantia nigra, globus pallidus, putamen, and caudate of both hemispheres) (Figure 1). MTRasym(3.5 ppm) and were measured for each region. The values of each side were recorded as a separate sample.

Figure 1

Examples of the definition of the regions of interest for quantitative analysis. (A) substantia nigra (green), (B) globus pallidus (blue), putamen (yellow) and caudate (red). MTRasym(3.5 ppm) and were measured for each region. The values of each side were recorded as separate samples.

Imaging analysis was carried out using FSL 4.0 software package (http://www.fmrib.ox.ac.uk/fsl). The first preprocessing step was to correct the motion effect and image distortion due to the eddy current. Next, skull stripping with the brain extraction tool (BET) was applied and brain masks were generated. Third, tensors were determined using DTIFIT, producing FA and MD maps.

We used ROI-based analysis in this study. The quantitative image analysis was performed by two radiologists (CL and RW), the same as CEST/APT imaging analysis. The b = 0 images were used as the anatomical reference to draw regions of interest (substantia nigra, globus pallidus, putamen, and caudate of both hemispheres) (Figure 2). FA and MD values were measured for each region. The values of each side were recorded as a separate sample. We covered the regions we concerned as much as possible, just the same as we do in CEST/APT analysis, to ensure the ROIs in CEST/APT and DTI were identical as much as possible.

Figure 2

Examples of the definition of the regions of interest for quantitative analysis. (A) substantia nigra (green), (B) globus pallidus (blue), putamen (yellow) and caudate (red). FA and MD were measured for each region. The values of each side were recorded as separate samples.

Statistical Analysis

All data were analyzed using the statistical package SPSS16.0. The average CEST imaging intensities [MTRasym(3.5 ppm) and ] and corresponding 95% confidence intervals were calculated for each region, as well as MD and FA values from DTI. Independent-samples t-tests were used to compare the differences in the parameters of CEST and DTI between PD patients and normal controls. Meanwhile, the PD patients were divided into two groups according to the H&Y stages (early stage: H&Y stages 1 and 2 vs. advanced stage: H&Y stages ≥2.5). The values of the parameters at different stages were also compared with one-way ANOVA. The level of significance was set at P < 0.05. We used post hoc tests to make multiple comparisons between every two groups. Tests of homogeneity of variances P values were used before the multiple comparisons. Tukey post hoc tests would be used with P ≥ 0.05, while Games-howell post hoc tests would be used with P < 0.05.

Results

Substantia Nigra

Table 1 shows the comparison of CEST/APT and DTI values in the substantia nigra for PD patients and for normal controls. The MTRasym(3.5 ppm) and values from CEST/APT, as well as the FA values from DTI, all showed significant differences on the substantia nigra in PD patients, compared with normal controls. Figure 3 shows the example images in regions of the substantia nigra of a PD patient and a normal control. The value difference between PD patient and normal control can be obviously seen in regions of the substantia nigra (black arrow) in APT-weighted image. However, the FA value difference between PD patient and normal control seemed to be unapparent in the substantia nigra (black arrow) though they have group differences.

Table 1

Comparisons of CEST/APT and DTI parameters values in the substantia nigra for Parkinson’s disease (PD) patients and normal controls (mean .

		Normal (n = 23)	PD (n = 23)	P values
CEST/APT	MTRasym(3.5 ppm)	1.25 ± 0.18	0.89 ± 0.15	0.003
	MTRasymtotal	3.45 ± 0.44	2.45 ± 0.50	0.004
DTI	FA	0.36 ± 0.02	0.32 ± 0.02	<0.001
	MD	0.68 ± 0.02	0.70 ± 0.03	0.400

MTR.

Figure 3

(A) FLAIR image, (B) APT-weighted image, (C) FA image, and (D) MD image of a PD patient (female; 53 years old; H&Y stage 3). (E) FLAIR image, (F) APT-weighted image, (G) FA image, and (H) MD image of a normal control (male; 65 years old). The CEST/APT imaging acquisition protocol provided B0 inhomogeneity-corrected, APT-weighted images with sufficient signal-to-noise ratios. The APT-weighted intensities in regions of the substantia nigra (black arrow) were lower in PD patient than in normal control. The FA values in regions of the substantia nigra (black arrow) seemed to be similar for this PD patient and normal control though they have group differences. The MD value in regions of the substantia nigra (black arrow) also seemed to be similar for this PD patient and normal control.

Table 2 compares the CEST/APT and DTI parameters values in the substantia nigra for normal controls and for early-stage and advanced-stage PD patients. The MTRasym(3.5 ppm) value, the value and FA value all showed significant differences between normal controls and advanced-stage PD. The MTRasym(3.5 ppm) value of the substantia nigra even decreased significantly from the normal controls to the early-stage PD (P = 0.032). A progressive decrease can be seen from normal controls, early-stage PD patients to late-stage PD patients for the MTRasym(3.5 ppm) value, the value and FA value. No significant differences were found for MD values.

Table 2

CEST/APT and DTI parameters values in the substantia nigra for normal controls and PD patients at different stages.

		Normal (n = 23)	Early-stage PD (n = 12)	Advanced-stage PD (n = 11)	Tests of homogeneity of variances P values	ANOVA			Multiple comparisons P values (95% confidence interval)
						df	F	P values
CEST/APT	MTRasym(3.5 ppm)	1.25 ± 0.18	0.96 ± 0.14	0.81 ± 0.29	0.035	2	5.248	0.007	0.032 (0.02, 0.54), 0.599 (−0.23, 0.54), 0.032 (0.03, 0.84)
	MTRasymtotal	3.45 ± 0.44	2.68 ± 0.50	2.21 ± 0.95	0.097	2	4.980	0.009	0.141 (−0.19, 1.73), 0.576 (−0.65, 1.59), 0.010 (0.26, 2.23)
DTI	FA	0.36 ± 0.02	0.34 ± 0.02	0.31 ± 0.03	0.790	2	9.630	<0.001	0.149 (−0.01, 0.05), 0.072 (−0.01, 0.07), <0.001 (0.03, 0.09)
	MD	0.68 ± 0.02	0.69 ± 0.03	0.70 ± 0.05	0.003	2	0.429	0.653	0.837 (−0.06, 0.04), 0.943 (−0.09, 0.07), 0.750 (−0.10, 0.05)

MTR.

Striatum (Globus Pallidus, Putamen, and Caudate)

Tables 3–5 show the comparisons of CEST/APT and DTI parameters values in the globus pallidus, putamen, and caudate for PD patients and normal controls, respectively. The MTRasym(3.5 ppm) values of the putamen and caudate were significantly higher in PD patients than in normal controls (P = 0.010 and P = 0.009, respectively). The MTRasym(3.5 ppm) value of the globus pallidus was also higher in PD patients than in normal controls, but the difference was not significant (P = 0.125). The of the globus pallidus, putamen and caudate were also higher in PD patients than in normal controls, but no significant differences were found (P = 0.259, P = 0.119, and P = 0.573, respectively). No significant differences were found for the FA and MD values of the globus pallidus, putamen, and caudate between PD patients and normal controls.

Table 3

Comparisons of CEST/APT and DTI parameters values in the globus pallidus for Parkinson’s disease (PD) patients and normal controls (mean .

		Normal (n = 23)	PD (n = 23)	P values
CEST/APT	MTRasym(3.5 ppm)	0.68 ± 0.17	0.84 ± 0.12	0.125
	MTRasymtotal	2.20 ± 0.29	2.48 ± 0.38	0.259
DTI	FA	0.25 ± 0.01	0.24 ± 0.02	0.122
	MD	0.70 ± 0.03	0.72 ± 0.03	0.227

MTR.

Table 5

Comparisons of CEST/APT and DTI parameters values in the caudate for Parkinson’s disease (PD) patients and normal controls (mean .

		Normal (n = 23)	PD (n = 23)	P values
CEST/APT	MTRasym(3.5 ppm)	0.84 ± 0.17	1.14 ± 0.14	0.009
	MTRasymtotal	2.79 ± 0.21	2.90 ± 0.35	0.573
DTI	FA	0.16 ± 0.01	0.15 ± 0.01	0.563
	MD	0.74 ± 0.03	0.75 ± 0.01	0.546

MTR.

Figure 4 shows the example images in the striatum of a PD patient and a normal control. The value difference between PD patient and normal control can be obviously seen in regions of the striatum (black arrow) in APT-weighted image, while no significant differences were found for the FA and MD images (black arrow).

Figure 4

(A) FLAIR image, (B) APT-weighted image, (C) FA image, and (D) MD image of a PD patient (male; 74 years old; H&Y stage 2.5). (E) FLAIR image, (F) APT-weighted image, (G) FA image, and (H) MD image of a normal control (male; 61 years old). The CEST/APT imaging acquisition protocol provided B0 inhomogeneity-corrected, APT-weighted images with sufficient signal-to-noise ratios. The APT-weighted intensities in regions of the striatum (black arrow) were higher in PD patient than in normal control. The FA and MD values in regions of the striatum (black arrow) seemed to be similar for this PD patient and normal control.

Tables 6–8 further compare CEST/APT and DTI values in the globus pallidus, putamen, and caudate for normal controls and early-stage and advanced-stage PD patients. It can be seen that the MTRasym(3.5 ppm) intensities of the putamen and caudate increased significantly from the normal controls to the early-stage PD (P = 0.016 and P < 0.001, respectively). The MTRasym(3.5 ppm) value of the globus pallidus was also higher in early-stage PD patients than in normal controls, but the difference was not significant (P = 0.212). Meanwhile, the MTRasym(3.5 ppm) of the caudate for PD patients showed a significant decrease from the early stage to the advanced stage (P = 0.013).

Table 6

CEST/APT and DTI parameters values in the globus pallidus for normal controls and PD patients at different stages.

		Normal (n = 23)	Early-stage PD (n = 12)	Advanced-stage PD (n = 11)	Tests of homogeneity of variances P values	ANOVA			Multiple comparisons P values (95% confidence interval)
						df	F	P values
CEST/APT	MTRasym(3.5 ppm)	0.68 ± 0.17	0.89 ± 0.14	0.78 ± 0.20	0.065	2	1.470	0.236	0.212 (−0.51, 0.09), 0.739 (−0.24, 0.45), 0.703 (−0.41, 0.20)
	MTRasymtotal	2.20 ± 0.29	2.60 ± 0.58	2.34 ± 0.53	0.827	2	0.927	0.400	0.366 (−1.09, 0.30), 0.731 (−0.55, 1.07), 0.889 (−0.85, 0.58)
DTI	FA	0.25 ± 0.01	0.23 ± 0.03	0.24 ± 0.03	0.162	2	1.284	0.282	0.294 (−0.01, 0.06), 0.921 (−0.05, 0.04), 0.565 (−0.02, 0.05)
	MD	0.70 ± 0.03	0.71 ± 0.04	0.73 ± 0.04	0.751	2	1.076	0.345	0.849 (−0.07, 0.04), 0.691 (−0.09, 0.04), 0.312 (−0.10, 0.02)

MTR.

Table 8

CEST/APT and DTI parameters values in the caudate for normal controls and PD patients at different stages.

		Normal (n = 23)	Early-stage PD (n = 12)	Advanced-stage PD (n = 11)	Tests of homogeneity of variances P values	ANOVA			Multiple comparisons P values (95% confidence interval)
						df	F	P values
CEST/APT	MTRasym(3.5 ppm)	0.84 ± 0.17	1.35 ± 0.14	0.91 ± 0.25	0.246	2	8.084	0.001	<0.001 (−0.82, −0.20), 0.013 (0.08, 0.80), 0.859 (−0.39, 0.25)
	MTRasymtotal	2.79 ± 0.21	3.06 ± 0.48	2.73 ± 0.54	0.008	2	0.850	0.431	0.531 (−0.90, 0.35), 0.601 (−0.51, 1.18), 0.974 (−0.63, 0.75)
DTI	FA	0.16 ± 0.01	0.16 ± 0.02	0.15 ± 0.01	0.099	2	0.514	0.600	1.000 (−0.02, 0.02), 0.684 (−0.01, 0.03), 0.604 (−0.01, 0.03)
	MD	0.74 ± 0.03	0.75 ± 0.02	0.74 ± 0.02	0.578	2	0.293	0.746	0.726 (−0.07, 0.04), 0.885 (−0.05, 0.07), 0.977 (−0.06, 0.05)

MTR.

No significant differences were found for the values, FA values, and MD values.

Discussion

In this study, we used two techniques, CEST/APT and DTI, to evaluate PD. The regions we focused on included the substantia nigra and striatum, for they are the main regions involved in PD. We aimed to compare the changes of these regions in PD by these two techniques and find out which can provide more information in the assessment of PD. To our knowledge, very few previous reports evaluated PD with CEST/APT and the present study was the first time to compare CEST and DTI in PD patients.

Chemical exchange saturation transfer imaging is a novel molecular MRI technique that can detect endogenous, low-concentration chemicals in tissue non-invasively (Cai et al., 2012; Haris et al., 2013; Walker-Samuel et al., 2013; Harston et al., 2015). More specifically, APT imaging (a type of CEST imaging, sensitive to amide protons resonating at 3.5 ppm from water) was designed to detect mobile (cytosolic) proteins and peptides. Previous study has indicated the possibility of using CEST/APT in the diagnosis of PD (Li et al., 2014). DTI based upon the diffusivity of water molecules has typically been used to study white matter tract. Although the concerned regions in this study are not the typical targets for DTI studies, diffusion anisotropy changes in gray matter have been reported in aging (Pfefferbaum et al., 2010), brain maturation (Mukherjee et al., 2002), and other neurological disorders (Bozzali et al., 2002). Thus, analyses have performed on gray matter area changes of PD in some studies and the results seemed to be variable.

Substantia Nigra Result Analysis

The substantia nigra showed significantly lower MTRasym(3.5 ppm) signal intensities and lower total CEST signal intensities in PD patients than in normal controls, which may suggest that the changes could be attributed to the loss of dopaminergic neurons or to the depletion of some chemicals with fast exchange protons, such as dopamine. This result is similar to the previous study (Li et al., 2014). FA values of the substantia nigra showed significant difference in PD patients, which may result from the loss of dopaminergic neurons and injury of axons. This result agreed with some publications (Vaillancourt et al., 2009; Du et al., 2012; Skorpil et al., 2012), but in contrast to some other reports showing small or no PD induced decreased FA (Menke et al., 2010; Focke et al., 2011; Kim et al., 2013; Aquino et al., 2014), or even increased nigral FA in PD patients (Wang et al., 2011). For MD values of the substantia nigra, no significant changes were found in PD patients compared to normal controls, though they seemed to have an increase tendency in PD patients. This agreed with some previous reports (Karagulle Kendi et al., 2008; Du et al., 2012; Aquino et al., 2014) but disagreed with some other reports (Gattellaro et al., 2009; Prakash et al., 2012), which found increased nigral MD values. Potential factors contributing to this study heterogeneity may be technical aspects resulting limited quality of FA or MD measurements and different study population characteristics, such as disease severity, as Stefan said in their meta-analysis (Schwarz et al., 2013). From our results, both CEST/APT and DTI parameters are able to differentiate PD from normal controls.

We further divided PD patients into two groups according to the H&Y stages (early stage: H&Y stages 1 and 2 vs. advanced stage: H&Y stages ≥2.5) to find out the CEST/APT and DTI changes in the substantia nigra in different stages of PD. The CEST intensity had a tendency to decrease gradually with the PD progression, no matter the MTRasym(3.5 ppm) signal intensities or the total CEST signal intensities. Meanwhile, the FA value also had similar decreased tendency in the progression of PD. As the FA value decrease in PD has been contributed to the continuous dopaminergic neurons loss, such results may provide us indirect evidence that CEST/APT can reveal the loss of dopaminergic neurons in PD (Kirik et al., 2002; Hodaie et al., 2007). However, the CEST/APT seemed to be superior to DTI in the further comparison of different groups. Significant differences were found for both MTRasym(3.5 ppm) and total CEST signal intensities between normal controls and advanced-stage PD. Moreover, the MTRasym(3.5 ppm) signal intensities of the substantia nigra has decreased significantly in PD patients even in early stage, which indicated the potential of CEST imaging to detect PD patients in early stage. In the other hand, FA values only showed significant differences between normal controls and advanced-stage PD and no significant differences were found for MD although they seemed to increase gradually in PD progression.

Striatum (Globus Pallidus, Putamen, and Caudate) Result Analysis

For CEST/APT, the MTRasym(3.5 ppm) signal intensities and total CEST signal intensities of the globus pallidus, putamen, and caudate were higher in PD patients than in normal controls though the changes in some regions were not significant. This may be associated with increased cytosolic proteins and peptides, as expected (Braak et al., 1999; Tong et al., 2010). When dividing PD patients into early stage and advanced stage, the CEST intensity changes for the globus pallidus, putamen, and caudate were more complicated. It seemed that both the MTRasym(3.5 ppm) signal intensities and the total CEST signal intensities reached to the peak at early stage and later dropped at advanced stage. For the putamen and caudate, the MTRasym(3.5 ppm) signal intensities even showed significant increases in early stage. This result is similar to the previous study (Li et al., 2014).This indicated CEST intensities in these three regions may play a more important part in the early diagnosis of PD, even though we are not sure the exact mechanism of their changes now. We can only presume the CEST intensities increased in early stage due to the increased of abnormal cytoplasmic proteins (such as α-synuclein) (Braak et al., 1999; Tong et al., 2010) and their decreases in advanced stage may associate with the neurons loss with PD progression or the treatment effect.

Compared with CEST/APT, DTI results seemed not promising. No significant differences were found between PD patients and normal controls in these regions, no matter MD or FA. Even when we further divided PD patients into two groups (early stage and advanced stage) to compare the FA and MD values of three groups, no significant differences were found for every two groups comparisons. Such results accorded with previous reports (Nicoletti et al., 2006; Gattellaro et al., 2009; Focke et al., 2011). In contrast, some studies got the result that these regions may have higher MD values (Kim et al., 2013) or lower FA values (Zhan et al., 2012) in PD. The reason for this inconsistency is not clear. However, we presume that the difference of PD population, scan protocol or the method of postprocessing including thresholding of FA and setting of significance level may be the potential factors.

Comparison of CEST/APT Imaging and DTI

From our results, CEST/APT imaging had provided more information than DTI in the differentiation of PD. Multiple regions revealed significant changes in the four regions in PD compared to normal controls by the parameters of CEST/APT imaging, while DTI only suggested the FA changes in the substantia nigra. Meanwhile, multiple regions, including the substantia nigra, putamen, and caudate, showed significant MTRasym(3.5 ppm) changes even in early stage of PD, which indicated their potential in the early diagnosis of PD. Moreover, the MTRasym(3.5 ppm) values of the caudate showed significant changes from early stage to advanced stage of PD, supplying information in the evaluation of PD progression. The FA values of the substantia nigra also decreased significantly from normal controls to advanced-stage PD, but no other significant changes were found for DTI neither in the comparison of normal controls and early-stage PD, nor the comparison of early stage and advanced stage. Though the results may be influenced by the patient population, scan protocol or postprocessing, which may cause the underestimation of the DTI utility in PD evaluation in this study, our preliminary results indeed revealed the superior utility of CEST/APT imaging in the evaluation of PD.

There were some limitations to this study. First, owing to the limitation of the single-slice acquisition protocol for CEST/APT imaging, only two slices were acquired in this study. Thus, we can evaluate the MRI signal changes in these two slices and other regions could not be included in the present study. This shortage may be overcome by 3D imaging acquisition sequence in the future, which has been reported (Zhou et al., 2013b). Second, the ROIs for CEST/APT imaging and DTI were selected respectively, which may cause mismatch of the ROIs selection. Besides, the limited resolution of CEST/APT imaging brought some difficulty for us to select these four small regions exactly for the quantitative analysis. This may influence the comparison result to some extent. Third, the sample number in the present study was relatively small and further studies with large sample analysis are needed to confirm these results.

In conclusion, CEST MR imaging provided multiple CEST signal differences in the regions of substantia nigra and striatum in PD and may be superior to DTI in the diagnosis and severity evaluation of PD. CEST MR imaging has the potential to differentiate PD patients in the early stage and to evaluate the progression of PD. In the coming work, more cases should be collected to confirm the utility of CEST MR imaging. Also, the mechanisms underlying such results should be studied.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Table 4

Comparisons of CEST/APT and DTI parameters values in the putamen for Parkinson’s disease (PD) patients and normal controls (mean .

		Normal (n = 23)	PD (n = 23)	P values
CEST/APT	MTRasym(3.5 ppm)	0.83 ± 0.13	1.06 ± 0.12	0.010
	MTRasymtotal	2.68 ± 0.25	3.01 ± 0.34	0.119
DTI	FA	0.14 ± 0.01	0.14 ± 0.01	0.520
	MD	0.72 ± 0.01	0.73 ± 0.01	0.142

MTR.

Table 7

CEST/APT and DTI parameters values in the putamen for normal controls and PD patients at different stages.

		Normal (n = 23)	Early-stage PD (n = 12)	Advanced-stage PD (n = 11)	Tests of homogeneity of variances P values	ANOVA			Multiple comparisons P values (95% confidence interval)
						df	F	P values
CEST/APT	MTRasym(3.5 ppm)	0.83 ± 0.13	1.12 ± 0.12	0.99 ± 0.20	0.279	2	4.142	0.019	0.016 (−0.54, −0.05), 0.500 (−0.15, 0.43), 0.314 (−0.41, 0.10)
	MTRasymtotal	2.68 ± 0.25	3.10 ± 0.46	2.92 ± 0.55	0.038	2	1.427	0.245	0.237 (−1.05, 0.20), 0.849 (−0.65, 1.03), 0.702 (−0.95, 0.48)
DTI	FA	0.14 ± 0.01	0.14 ± 0.02	0.14 ± 0.01	0.260	2	0.250	0.779	0.766 (−0.02, 0.01), 0.954 (−0.02, 0.02), 0.937 (−0.02, 0.02)
	MD	0.72 ± 0.01	0.72 ± 0.02	0.74 ± 0.02	0.505	2	2.046	0.135	0.889 (−0.03, 0.02), 0.360 (−0.05, 0.01), 0.116 (−0.05, 0.01)

MTR.